Maze Therapeutics (MAZE) News
NASDAQ: MAZEHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
31.37-1.06 (-3.27%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
MAZE news summary
We found 3 recent headlines mentioning Maze Therapeutics (MAZE): 0 in the past week and 3 in the past 30 days, most often from GlobeNewswire, Seeking Alpha. For price context, MAZE is down 3.27% at $31.37. The most recent story, "Maze Therapeutics GAAP EPS of -$0.79", was published by Seeking Alpha on Nov 10, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Maze Therapeutics headlines
- Maze Therapeutics GAAP EPS of -$0.79Seeking Alpha
- Maze Therapeutics Reports Third Quarter 2026 Financial Results and Recent HighlightsEnrollment completed in Phase 2 HORIZON trial of MZE829; data from all three cohorts expected in early 2027GlobeNewswire
- Maze Therapeutics to Participate in Upcoming Investor ConferencesSOUTH SAN FRANCISCO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for…GlobeNewswire